Bailey R C, Kamenga M C, Nsuami M J, Nieburg P, St Louis M E
Division of Epidemiology, School of Public Health, University of Illinois at Chicago 60612, USA.
Int J Epidemiol. 1999 Jun;28(3):532-40. doi: 10.1093/ije/28.3.532.
Most HIV-infection in children occurs in sub-Saharan Africa where antiretroviral therapy is seldom available. This study compares the growth progression and retardation of HIV-infected and uninfected children in the Democratic Republic of Congo (formerly Zaire). It estimates the risk for child growth retardation according to child and maternal immunological factors, severity of maternal and child illness, and maternal socioeconomic and marital status.
In a prospective cohort study of 258 children born to HIV seropositive mothers and 256 children of seronegative mothers in Kinshasa, Congo, the growth in length, weight, and weight-for-length of infected children (n = 68), uninfected children born to seropositive mothers (n = 190), and uninfected children born to uninfected mothers (n = 256) was compared. Serological, anthropometric and other clinical measures were collected monthly from 3-12 months and bi-monthly during the second year of life. Polymerase chain reaction for HIV was performed on bloods drawn at 2 days and 3 months post partum. Length-for-age, weight-for-age, and weight-for-length mean z-scores against National Center for Health Statistics (NCHS) reference data were calculated, and Cox proportional hazards models were used to estimate the risk of falling below -2.00 z-scores as a function of child and maternal immunological, clinical and sociodemographic variables.
There was no difference in mean length-for-age at birth between HIV-infected (Group 1) children, uninfected children of infected mothers (Group 2) or Control children, but by 3 months old, HIV-infected children were shorter than both Group 2 and Controls. In weight-for-age and weight-for-length, Group 1 infants were lighter and more wasted at birth and onwards. Group 2 newborns were lighter than Controls at birth, but by three months they had caught up to Controls in both length and weight and remained the same as Controls thereafter. The odds of falling below -2.00 z-scores by 20 months for length, weight, and weight-for-length for HIV-infected children compared to uninfected children were 2.10, 2.84, and 2.56 respectively. Both HIV-infection and associated illnesses were factors associated with child stunting, underweight and wasting. The mother's age, socioeconomic status, presence of father, stage of illness and immune status had no detectable effect on the child's growth in the first two years of life.
The HIV-infected children in Congo with no access to antiretroviral therapy were stunted, underweight, and wasted compared to same age uninfected children. Both HIV infection and HIV-associated signs and symptoms, not maternal immunological or socioeconomic circumstances, placed children at risk for growth retardation.
大多数儿童艾滋病毒感染发生在撒哈拉以南非洲,那里很少有抗逆转录病毒疗法。本研究比较了刚果民主共和国(原扎伊尔)感染艾滋病毒和未感染艾滋病毒儿童的生长进程和发育迟缓情况。它根据儿童和母亲的免疫因素、母婴疾病的严重程度以及母亲的社会经济和婚姻状况,估计儿童发育迟缓的风险。
在刚果金沙萨对258名艾滋病毒血清阳性母亲所生儿童和256名血清阴性母亲所生儿童进行的一项前瞻性队列研究中,比较了感染儿童(n = 68)、血清阳性母亲所生未感染儿童(n = 190)和未感染母亲所生未感染儿童(n = 256)的身长、体重和身长别体重的增长情况。在出生后3至12个月每月收集血清学、人体测量学和其他临床指标,在生命的第二年每两个月收集一次。对产后2天和3个月抽取的血液进行艾滋病毒聚合酶链反应检测。根据美国国家卫生统计中心(NCHS)的参考数据计算年龄别身长、年龄别体重和身长别体重的平均z评分,并使用Cox比例风险模型估计低于-2.00 z评分的风险,该风险是儿童和母亲的免疫、临床和社会人口学变量的函数。
艾滋病毒感染儿童(第1组)、感染母亲所生未感染儿童(第2组)或对照儿童在出生时的平均年龄别身长没有差异,但到3个月大时,艾滋病毒感染儿童比第2组和对照组儿童都矮。在年龄别体重和身长别体重方面,第1组婴儿在出生时及以后体重更轻,消瘦更严重。第2组新生儿出生时比对照组轻,但到3个月时,他们在身长和体重方面都赶上了对照组,此后一直与对照组相同。与未感染儿童相比,艾滋病毒感染儿童在20个月时身长、体重和身长别体重低于-2.00 z评分的几率分别为2.10、2.84和2.56。艾滋病毒感染和相关疾病都是与儿童发育迟缓、体重不足和消瘦相关的因素。母亲的年龄、社会经济地位、父亲的存在、疾病阶段和免疫状态在前两年对儿童生长没有可检测到的影响。
与同龄未感染儿童相比,刚果无法获得抗逆转录病毒疗法的艾滋病毒感染儿童发育迟缓、体重不足且消瘦。艾滋病毒感染以及与艾滋病毒相关的体征和症状,而非母亲的免疫或社会经济状况,使儿童面临发育迟缓的风险。